Navigation Links
Elsevier announces the 2008 supplement of Reproductive Health Matters
Date:12/2/2008

Amsterdam, 2 December 2008 - Elsevier announced today the publication of Reproductive Health Matters 2008 Supplement on the theme of "Second trimester abortion: women's health and public policy". Second trimester abortion raises complex issues regarding methods, values, stigma, the burden on providers of service delivery and the sometimes complicated reality of women's lives and decisions. This issue of Reproductive Health Matters grew out of a conference on second trimester abortion convened in London in 2007 by the International Consortium on Medical Abortion and attended by 90 expert clinicians and advocates from all over the world.

In many countries, legislation prohibits or restricts the grounds for second trimester abortions. Instead of preventing women from having abortions, these laws often force them to risk their lives doing so. There will always be women who need abortions after 12 weeks of pregnancy, but the numbers diminish greatly by 20 weeks, and become rare after 24 weeks.

Abortion-related deaths have been declining globally in the past three decades because many more countries now have safe, legal abortion. Methods have become substantially safer and simpler, more providers have been trained, and women with complications are more likely to seek and to receive medical help, even where abortion is still legally restricted.

This issue calls for the need for second trimester abortion to be met in a safe, timely and sympathetic manner In-depth, country-based research is needed, to bring out the facts on second trimester abortion, as evidence of why it should be treated as a legitimate form of women's health care and supported in public health policy. Papers in this supplement cover the law and safety of second trimester abortion; women's and providers' perspectives; policy, politics and values; moving from unsafe to safe service delivery; currently recommended methods; methods that should go out of use;
'/>"/>

Contact: Minke Havelaar
m.havelaar@elsevier.com
31-204-853-122
Elsevier
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Elsevier launches new journal: Stem Cell Research
2. Elsevier announces new journal on inflammatory bowel diseases
3. Roy Jakobs Appointed Elsevier Managing Director, A&G Sales and Customer Marketing
4. Excerpta Medica and Elsevier Interactive Solutions merge into 1 integrated provider
5. Elsevier journals participate widely in global theme issue on poverty and human development
6. ScienceDirect to host French-language journals from Elsevier Masson
7. Elseviers "WiserWiki" Allows Physicians to Update Evidence-Based Medical Information With Experience-Based Practice Insights
8. Elseviers WiserWiki allows physicians to update evidence-based medical information
9. Elsevier Foundation Announces Grants for Innovative Libraries and New Scholars
10. Elsevier Foundation announces grants for innovative libraries and new scholars
11. Elsevier enhances clinical decision making with suite of Clinical Decision Support solutions

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...e funds to move lab findings into human therapy fo...from nerve damage ,, ANN ARBOR, Mich., Nov. 9 ...versity of Michigan Department of Neurology have r...erapy for neuropathic pain, a difficult-to-treat c... of damage to nerve without obvious tissue injury....
(Date:11/9/2009)...e in French . , , Montreal, November 9, 2009...ale. In human bodies trillions of cells are couple...re composed. Yet these don,t come in twos, they a...use these complex cell networks are the backbone o... for ways to splice cell clusters down to their or...
(Date:11/9/2009)... 2009 Shire plc (LSE: SHP, NASDAQ: SHPGY), the gl...nounced the availability of INTUNIV (guanfacine) E...nited States for the treatment of Attention-Defici...olescents ages 6 to 17. INTUNIV, a once-daily for...cheduled alpha-2A receptor agonist approved for th...
(Date:11/9/2009)...ple around the world suffer from cataracts. Thomas...his coauthors discuss cataract surgery with the im...sue of Deutsches rzteblatt International ( Dtsch...ndness is usually due to opacification of the lens...rations are performed each year. Cataracts can be ...
(Date:11/9/2009)... people have tried to read Charles Darwin,s "Origi...0th anniversary this month, but gave up. , For t...k is about, help by way of a new book is at hand. ...eznick is the author of "The Origin Then and N...s " (Princeton University Press, 2009), which mak...
Breaking Medicine News(10 mins):Health News:U-M Researchers Receive $1.8 Million Grant to Develop New Therapy for Neuropathic Pain 2Health News:Once-daily INTUNIV (guanfacine) extended release tablets now available in US pharmacies 2Health News:Once-daily INTUNIV (guanfacine) extended release tablets now available in US pharmacies 3Health News:Once-daily INTUNIV (guanfacine) extended release tablets now available in US pharmacies 4Health News:Book by UC Riverside biologist explains Darwin's 'Origin of Species' 2
...disorders among adolescent girls and boys can have...ead to dangerous weight-control behaviors, such as...t pills to control weight. The middle school age i... at the Harvard School of Public Health (HSPH) set...
...d number of youth with office visits with a diagno...tween 1994 and 2003, while adult visits with a bip... according to a report in the September issue of A...a (an abnormally elevated mood) and depression. Al...
... "Psoriasis Cure,Now," a nonprofit patient advoca... parents of children with psoriasis as their kids ...e fact sheet on children,s psoriasis,that parents ...discussing how to treat psoriasis in children and ...
...er 3 KFH has announced that it,has succeeded in o...SO,9001:2000 quality management systems with the B... Director, Dr Sally Sennitt, MD, says: "We are del...d,one that very few young medical device companies...
... data about the safety of drug-,eluting stents (DE...,patients with cardiovascular disease, according t...nterventions (SCAI). These new findings,also under...gimen of medications that prevent blood clots in t...
...fforts to control population growth in the present...s in the future. , This prediction comes from a S...r who spent a year in China studying its geriatric...niversity, said Chinas 1979 policy of limiting cou...
Other Medicine News:Health News:School-based overweight prevention program may cut risk of eating disorders among girls 2Health News:Study documents rapid increase in youth bipolar disorder diagnoses 2Health News:Psoriasis Cure Now offers 'Back to School' Resources for Parents of Children with Psoriasis 2Health News:Latest DES Analysis Stresses Importance of Physicians Well-Trained in Implantation Technique and Patient Follow-Up 2Health News:Latest DES Analysis Stresses Importance of Physicians Well-Trained in Implantation Technique and Patient Follow-Up 3Health News:China's 1-child policy could backfire on its elderly 2Health News:China's 1-child policy could backfire on its elderly 3
(Date:11/9/2009)...ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), today...epreve(TM) (bepotastine besilate ophthalmic soluti...were presented in poster sessions at the 2009 Annu...hma & Immunology (ACAAI) in Miami Beach, FL. ...of Ocular Itching with Bepotastine Besilate Ophtha...
(Date:11/9/2009)...ll/ -- Arcadia Resources, Inc. (NYSE Amex: KAD ),...care services under the Arcadia HealthCare(SM) bra...f Directors. Goldsmith will replace Tres Lund who..., (Photo: http://www.newscom.com/cgi-bin/prnh/20...aul Professor of Government and Director of Innova...
(Date:11/9/2009)...ia/ -- Chindex International, Inc.,("Chindex") (Na...ider of Western,healthcare products and services i...results for the second quarter and first half of f... Financial Highlights:, -- Revenue in the seco...on, a year over year basis;, -- Net incom...
Breaking Medicine Technology:ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) 2ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) 3Arcadia Resources Names Stephen Goldsmith to Board of Directors 2Arcadia Resources Names Stephen Goldsmith to Board of Directors 3Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 2Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 3Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 4Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 5Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 6Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 7Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 8Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 9Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 10Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 11Study of agricultural watersheds and carbon losses 8933 1Study of agricultural watersheds and carbon losses 8933 2Domestication of Capsicum annuum chile pepper provides insights into crop origin and evolution 8931 1Domestication of Capsicum annuum chile pepper provides insights into crop origin and evolution 8931 2Children 26apos 3Bs National Medical Center Dedicates New Blood Donor Center 49506 1Children 26apos 3Bs National Medical Center Dedicates New Blood Donor Center 49506 2Children 26apos 3Bs National Medical Center Dedicates New Blood Donor Center 49506 3
...euticals, Inc. (Nasdaq: ARNA ) announced today th...rial of APD125 in patients with primary,insomnia. ...na with the,potential to reduce insomnia symptoms ...hase 2b trial of APD125 is a double-blind, randomi...ng the efficacy and tolerability of,APD125 in pati...
...Navigenics, a,genetic health services company, tod... analysis. The Mayo Clinic study will examine how ...y a Navigenics genetic risk,assessment. The resear...etic assessments and the impact of such informatio...Proof of Principle Trial of Communication to,Patie...
Other Medicine Technology:Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia 2Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia 3Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia 4Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia 5Navigenics'(TM) Genome Analysis Used In Research Trial on the Impact of Providing Genetic Risk Assessments 2
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
Medicine Products: